Aitokallio-Tallberg A, Viinikka L, Ylikorkala O
First and Second Department of Obstetrics and Gynaecology, University of Helsinki, Finland.
Br J Cancer. 1989 Nov;60(5):785-8. doi: 10.1038/bjc.1989.360.
We studied the effect of ovarian cancer and its chemotherapy on the urinary excretion of prostacyclin (PGI2) and thromboxane A2 (TxA2) hydration and metabolic products. In six patients we measured 6-keto-PGF1 alpha and 2,3-dinor-6-keto-PGF1 alpha (PGI2 products) and thromboxane B2 (TxB2) and 2,3-dinor-TxB2 (TxA2 products) by HPLC followed by radioimmunoassay before, during and after the combined infusion of cisplatin, 4'epi-adriamycin and cyclophosphamide. Before the first cytostatic infusion, the urinary excretion of prostanoids was on average 4.4-5.8 times higher than in patients with ovarian endometriosis (n = 19). The infusion of cytostatics led to a 50-120% rise in the excretion of prostanoids during the first post-infusion 9 hours, but in the subsequent 10 hours their output was 25-45% below the initial value and remained low for at least 2 weeks. Following repetitive courses of cytostatics (2-4 per patient), prostanoid excretion tended to normalise. These data suggest that ovarian cancer is associated with increased production of PGI2 and TxA2, and that cytostatics suppress this production. This may be of biological significance in tumour behaviour and in the effect of cytostatics.
我们研究了卵巢癌及其化疗对前列环素（PGI2）和血栓素A2（TxA2）水合及代谢产物尿排泄的影响。我们选取了6例患者，在联合输注顺铂、表阿霉素和环磷酰胺之前、期间及之后，通过高效液相色谱法继以放射免疫分析法测定6-酮-前列腺素F1α及2,3-二去甲-6-酮-前列腺素F1α（PGI2产物）以及血栓素B2（TxB2）和2,3-二去甲-血栓素B2（TxA2产物）。在首次细胞毒性药物输注前前列腺素的尿排泄量平均比卵巢子宫内膜异位症患者（n = 19）高4.4 - 5.8倍。细胞毒性药物输注导致输注后首个9小时内前列腺素排泄量增加50 - 120%，但在随后的10小时其排出量比初始值低25 - 45%，且至少持续2周保持在低水平。在进行重复疗程的细胞毒性药物治疗后（每位患者2 - 4个疗程），前列腺素排泄量趋于正常。这些数据表明卵巢癌与PGI2和TxA2生成增加有关，且细胞毒性药物可抑制这种生成。这在肿瘤行为及细胞毒性药物的作用方面可能具有生物学意义。
